Description

Paclivista Concentrate for Infusions 6 mg/ml. 50 ml. (300 mg.) №1

Ingredients:

Each ml contains 6 mg of Paclitaxel.

Dosage:

The recommended dosage is determined by a healthcare provider based on individual factors. It is typically administered intravenously over a specific period.

Indications:

Paclivista concentrate is indicated for the treatment of various cancers, including breast, lung, and ovarian cancers. It works by interfering with the growth and spread of cancer cells in the body.

Contraindications:

Do not use Paclivista concentrate if you are allergic to paclitaxel or have certain medical conditions. Always consult with a healthcare provider before starting treatment.

Directions:

Administered by a healthcare professional through a vein (intravenously) over 3 hours. The dosage and treatment schedule will be determined by your healthcare provider.

Scientific Evidence:

Paclivista concentrate for infusions has been extensively studied in clinical trials for its efficacy in treating various types of cancer. Research has shown that paclitaxel, the active ingredient in Paclivista, disrupts microtubule function in cancer cells, leading to cell death. This mechanism makes it a valuable treatment option in oncology.

Additional Information:

It is essential to monitor for potential side effects during treatment with Paclivista concentrate. Common side effects may include nausea, hair loss, and low blood cell counts. Patients should be closely monitored by healthcare providers to manage any adverse reactions effectively.

Paclivista concentrate offers a targeted approach to cancer treatment, aiming to inhibit cancer cell growth and proliferation. By understanding the pharmacological action of paclitaxel, healthcare providers can tailor treatment plans to individual patients, optimizing therapeutic outcomes.